Nisa Investment Advisors LLC Purchases 10,121 Shares of Guardant Health, Inc. $GH

Nisa Investment Advisors LLC increased its holdings in Guardant Health, Inc. (NASDAQ:GH) by 364.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,895 shares of the company’s stock after buying an additional 10,121 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Guardant Health were worth $2,300,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. The Manufacturers Life Insurance Company purchased a new position in Guardant Health during the 2nd quarter worth approximately $208,592,000. William Blair Investment Management LLC purchased a new stake in shares of Guardant Health in the 2nd quarter valued at $196,737,000. Orbimed Advisors LLC purchased a new position in shares of Guardant Health during the first quarter worth $40,199,000. Eagle Health Investments LP acquired a new position in Guardant Health during the second quarter valued at $45,112,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Guardant Health during the second quarter valued at $32,316,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Price Performance

Shares of NASDAQ GH opened at $169.08 on Friday. The stock has a market capitalization of $22.69 billion, a price-to-earnings ratio of -48.45 and a beta of 1.58. The firm’s 50 day simple moving average is $168.04 and its 200-day simple moving average is $141.69. Guardant Health, Inc. has a 12 month low of $68.02 and a 12 month high of $191.05.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.34. The firm had revenue of $334.98 million during the quarter, compared to analyst estimates of $314.23 million. During the same quarter in the prior year, the firm earned ($0.44) earnings per share. The business’s revenue for the quarter was up 44.3% on a year-over-year basis. Analysts anticipate that Guardant Health, Inc. will post -3.02 earnings per share for the current fiscal year.

Insider Activity at Guardant Health

In related news, insider Terilyn Monroe sold 46,300 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the sale, the insider owned 22,979 shares in the company, valued at approximately $3,794,292.48. This trade represents a 66.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Steve Krognes sold 6,674 shares of Guardant Health stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $175.74, for a total transaction of $1,172,888.76. Following the completion of the transaction, the director directly owned 7,906 shares of the company’s stock, valued at $1,389,400.44. The trade was a 45.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 178,940 shares of company stock valued at $30,070,911 in the last quarter. 5.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have commented on GH. Guggenheim upped their price target on shares of Guardant Health from $190.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, October 1st. BTIG Research reiterated a “buy” rating and set a $195.00 price objective on shares of Guardant Health in a research note on Wednesday, September 2nd. Morgan Stanley boosted their price objective on Guardant Health from $185.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, October 12th. TD Cowen reissued a “buy” rating on shares of Guardant Health in a report on Tuesday, August 25th. Finally, JPMorgan Chase & Co. upped their target price on Guardant Health from $185.00 to $195.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $190.40.

About Guardant Health

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.